Business Wire

ExOne Reveals Advanced InnoventPro Metal 3D Printer Concept, Offering All-New Features in Binder Jetting

22.9.2020 15:00:00 EEST | Business Wire | Press release

Share

The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today debuted a concept rendering of the InnoventPro, a preview of the world’s most advanced entry-level binder jetting system for printing metals, ceramics and composites.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005243/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The InnoventPro (left) is an advanced entry-level metal 3D printer that rounds out ExOne's full family of production metal binder jetting systems, which includes the X1 25Pro (center) and the X1 160Pro (far right). ExOne is also introducing the X1D1 automated guided vehicle for efficient Industry 4.0 transport of heavy build boxes from 3D printing through final sintering operations. (Photo: Business Wire)

The InnoventPro will be a major upgrade of the Innovent+, the world’s best-selling metal binder jetting system since 2016. The InnoventPro will offer two new build sizes, a 3-liter and a 5-liter, with print speeds topping 700 cc/hour. The updated system is aimed at academics, researchers, and a full spectrum of manufacturers, from machine and MIM shops to high-volume producers, who want to produce metal parts quickly, affordably and sustainably.

“Customers around the world already love the Innovent+, and based on their feedback, we’re going to give them an updated entry-level system that’s bigger, faster and smarter than ever,” said John Hartner, ExOne CEO.

Siemens Digital Industries will serve as an Industry 4.0 collaboration partner on the production version of the machine, to be unveiled in the second half of 2021. An incentive program for the InnoventPro will be offered to customers who buy an Innovent+ prior to commercial availability of the new system. Learn more at www.exone.com/InnoventPro

Raising the bar in binder jetting

Binder jetting is a groundbreaking 3D printing process that uses a digital file to quickly inkjet a binder into a bed of powder particles — metal, sand or ceramic — creating a solid part one layer at a time. When printing metals, the final part must be sintered in order to fuse the particles together into a solid object.

Binder jetting is a sustainable method of manufacturing that reduces material waste to less than 5%, saves energy by consolidating many assembled parts and processes into one, and can deliver end-use products that are 30-40% lighter — for more efficient cars, planes and military equipment.

Importantly, the new InnoventPro will feature the same recirculating printhead modules used on the X1 25Pro® and X1 160Pro metal 3D printers, allowing users to easily scale up from R&D to high-volume production.

The recirculating printhead also enables ExOne’s pioneering move to offer particulate binders as an option on a commercial binder jetting system. The ExOne research team has been 3D printing a variety of nanoparticles suspended in its binders for years.

All-New Class of NanoFuse Binders

First patented in 2018, with related patents pending worldwide, ExOne’s “inkjet-printable nanoparticle suspensions” are slated for commercial deployment in the InnoventPro. This all-new class of ExOne NanoFuse binders advances the field of binder jet 3D printing in critical ways.

Because nanoparticles fill in the interstices between powder bed particles and can bond at lower temperatures, they enable stronger green parts. In turn, this enables 3D printing of larger parts and finer features, delivering sharper corners and edges. These new binders can also improve the resolution and sinterability of high-demand metals, such as copper and aluminum.

Rick Lucas, ExOne CTO and VP, New Markets, said the InnoventPro and new NanoFuse binders show how ExOne continues to lead the way in commercial development of binder jetting.

“Just as the current Innovent+ served as the proving ground for our patented Triple ACT system, which now delivers industry-leading quality in metal binder jetting, the InnoventPro will offer groundbreaking new features in a commercial system,” Lucas said. “Our patented approach to 3D printing particulate inks in a print bed is opening new doors in binder jetting.”

ExOne’s patented Triple ACT is a critical advanced compaction technology that, depending on material, delivers industry-leading final part density of 97+%, dimensional tolerances in the range of <1%-2.5%, and high consistency, with part variation of just 0.3% across the print bed.

Triple ACT has been so effective that it has also sped up ExOne’s qualification of new materials. ExOne binder jet systems now process more than 20 metal, ceramic and composite materials, with single-alloy metals making up more than half of those offerings. NanoFuse binders are expected to expand that material range and improve sintering dynamics.

A webinar about NanoFuse will be held at 9 a.m. on Wednesday, Nov. 4. Details are available at https://tinyurl.com/NanoFuseWebinar.

About ExOne

ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Sarah Webster
Global Marketing Director
724-516-2336
sarah.webster@exone.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 18:08:00 EEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubrutinib) plus next-generation BCL2 inhibitor BEQALZI™ (sonrotoclax; ZS), which continue to demonstrate rapid, deep, durable responses across multiple B-cell malignancies. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “BTK inhibition has reshaped the treatment of B-cell cancers, and we believe degradation is the next leap forwa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye